BioMarin Begins Phase IIIb Study Evaluating Kuvan on Neuropsychiatric Symptoms

BioMarin Pharmaceutical announced on Tuesday that the first subject has initiated treatment in a Phase IIIb study to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria.  
TradersHuddle